-+ 0.00%
-+ 0.00%
-+ 0.00%

Arrowhead says EU CHMP backs REDEMPLO approval for familial chylomicronemia syndrome

PUBT·04/24/2026 10:39:17
Listen to the news
Arrowhead says EU CHMP backs REDEMPLO approval for familial chylomicronemia syndrome
  • EMA CHMP issued positive opinion backing EU approval of Arrowhead siRNA drug Redemplo (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome.
  • European Commission decision on marketing authorization expected in Q2 2026.
  • Phase 3 PALISADE trial showed 25 mg Redemplo cut triglycerides by median 80% versus 17% with placebo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260423566221) on April 24, 2026, and is solely responsible for the information contained therein.